Health Canada to Review ALS Drug (edaravone)

Health Canada has accepted Mitsubishi Tanabe Pharma Corporation’s New Drug Submission (NDS) for edaravone to treat patients with amyotrophic lateral sclerosis (ALS). Health Canada has also granted the drug a Priority Review so that it should take less than 6 months for the review process to be completed.

Read More

The Drug Review Process in Canada

Anyone who has participated in the Canadian healthcare system understands that it is complicated. And like many endeavours, the more government agencies involved, the more complicated (and convoluted) it seems to get. The same is true for the approval and disbursement of new medicines.

Read More

Patient Input for Drug Reviews

Once a drug is approved by Health Canada, the next step is for the drug company to submit information about the drug’s efficacy, safety, and pricing to the Canadian Agency for Drugs and Technologies in Health (CADTH) as well the various provincial health ministries. The agencies will also accept patient groups’ input.

Read More